ClinicalTrials.gg
Not yet recruitingNCT07684040ArcherUpdated Jul 6, 2026

A Study of Combination Therapy in Patients With Resectable Liver Cancer

A Phase 2 interventional study of Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib in Liver Cancer (Primary and Metastatic), sponsored by Affiliated Hospital of Guangdong Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Affiliated Hospital of Guangdong Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 310 studies in Liver Neoplasms with a site in China — 123 open to participants now, 135 under way, 7 of them phase 3. Liver Neoplasms · China.

Planned enrollment
132nd of 236
68 · median 80
Started
2026
with 24 others
Phase 2
36 of 310
17 open now
Primary completion
2030-07
later than 128 of 134 live
Registered
299th of 310
by date

Among the 310 studies in Liver Neoplasms with a site in China, this one is the 132nd largest by planned enrollment of the 236 interventional ones that give a count, is one of 25 that started in 2026, is one of 36 in phase 2, reaches primary completion later than 128 of the 134 other live ones, and was the 299th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

123 of the 310 studies in Liver Neoplasms with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Liver Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer. Eligible participants will receive combination therapy prior to surgical intervention. Patients who meet predefined surgical criteria will undergo hepatic resection. Following surgery, additional treatment may be administered according to the investigator's assessment. The primary objective is to evaluate time to treatment failure (TTF). Secondary objectives include evaluation of pathological response, resection outcomes, progression-related outcomes, survival outcomes, and safety.

03

Conditions studied

  • Liver Cancer (Primary and Metastatic)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily signed written .
  • 2. Age ≥18 years; male or female.
  • 3. Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) according to EASL/AASLD criteria.
  • 4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus).
  • 5. Presence of vascular invasion and no extrahepatic , including PVTT (Vp1-Vp3), HVTT, or IVCTT.
  • 6. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy.
  • 7. class A liver function.
  • 8. performance status 0-1.
  • 9. Adequate organ function:

    1. ≥1.5 × 10\^9/L; count ≥75 × 10\^9/L; ≥90 g/L.
    2. Albumin ≥30 g/L; Total ≤1.5 × ; , AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or >50 mL/min.
    3. ≤2.3 or PT prolongation ≤6 seconds.
    4. Urine protein \<2+; if ≥2+, 24-hour urine protein \<1.0 g.
  • 10. For patients with active infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment.
  • 11. Women of must have a negative pregnancy test before enrollment and agree to use effective during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion.

Exclusion criteria

Exclusion Criteria:

  • 1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active within the past 5 years (except HCC).
  • 2. Severe allergy to iodinated contrast agents that prevents HAIC treatment.
  • 3. Planned or prior organ transplantation or bone marrow transplantation.
  • 4. Treatment with another drug within 28 days before study treatment.
  • 5. Current or prior central nervous system .
  • 6. History of hepatic encephalopathy.
  • 7. Current interstitial pneumonitis or interstitial lung disease.
  • 8. Active disease or history of autoimmune disease with risk of recurrence.
  • 9. Use of agents or systemic for immunosuppressive purposes within 14 days before study treatment.
  • 10. Severe infection within 4 weeks before study treatment.
  • 11. Gastrointestinal bleeding within 6 months before study treatment or a known risk of gastrointestinal bleeding.
  • 12. Known hereditary or acquired bleeding disorders or thrombotic tendency.
  • 13. Uncontrolled cardiac disease or symptoms.
  • 14. Moderate or severe ascites requiring therapeutic drainage or paracentesis.
  • 15. Major vascular disease within 6 months before study treatment.
  • 16. Inability to swallow oral medication, malabsorption syndrome, or any condition affecting gastrointestinal absorption.
  • 17. Known to any study drug, its , monoclonal antibodies, or anti-angiogenic agents.
  • 18. Any other serious acute or chronic medical condition, psychiatric disorder, or laboratory abnormality that may increase study risk, interfere with study results, or make the patient unsuitable for participation.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Combination Therapy Followed by Surgery

    Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib

Interventions

  • DrugHepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib

    Surgery followed by Hepatic Arterial Infusion Chemotherapy Combined wit Adebrelimab plus Rivoceranib

06

What researchers measure

Primary outcomes

  1. Time to Treatment Failure

    Time from initiation of treatment to treatment failure, including disease progression resulting in inability to undergo surgery, recurrence/metastasis after surgery, or death from any cause.

    Time frame: 24 months

Secondary outcomes

  1. OS

    Overall survival (OS) after treatment, defined as the time from the start of treatment to death from any cause

    Time frame: 24 months

  2. R0 rate

    R0 rate, defined as the proportion of patients who accomplish the complete resection of tumor with pathologically confirmed negative margin

    Time frame: 24 months

  3. pCR rate

    Pathological complete regression (pCR) rate, defined as the proportion of patients with no evidence of vital residual tumor cells on the complete resected specimen. pCR status will be analyzed by local pathologists at each site

    Time frame: 24 months

  4. ORR

    Objective response rate (ORR) , defined as the proportion of patients with a complete response (CR) or partial response (PR), as determined by the investigator according to RECIST v1.1 and HCC mRECIST

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2030, 47 months later.

Of 73 non-industry phase 2 interventional studies under Liver Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 103. This study's planned 47 months is below that.

Counting every sponsor, half of 87 studies reached it within 57 months; a quarter within 37 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 6, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 1, 2030
CompletionEst.
Oct 1, 2030
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684040
Lead sponsor
Affiliated Hospital of Guangdong Medical University
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 1, 2030 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Jul 6, 2026

Study contacts

Wei Dai, M.D, PhD
Contact
dwgdmufy@gdmu.edu.cn
86 + 13828264321

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion